Table 2.

Concentrations of raltegravir in blood plasma and cervicovaginal fluids and concurrent viral loads in both compartments^a

Patientb	Time (h:min) between last drug intake and sampling of:		BP RAL concn (ng/ml)	CVF RAL concn (ng/ml)	Ratio of RAL to CVF in BP	BP HIV-1 RNA (copies/ml)	CVF HIV-1 RNA (copies/ml)
	BP	CVF
1	16:28	16:39	90	112	1.2	169	<200
2	Data missing	Data missing	46	113	2.5	<40	<200
3	15:00	15:30	47	904	19.2	<40	<200
4*	13:17	13:32	38	77	2.0	<40	<200
5	12:00	14:15	96	127	1.3	88	<200
6	05:45	06:00	873	273	0.3	<40	<200
7	14:20	15:00	358	197	0.6	<40	<200
8	12:05	13:15	609	1,062	1.7	<40	<200
9*	14:00	14:30	117	1,154	9.9	<40	<200
10*	12:20	13:00	130	4,782	36.8	<40	<200
11	14:20	14:50	73	273	3.7	<40	<200
12	14:00	13:00	179	389	2.2	<40	<200
13	13:45	13:10	51	160	3.1	<40	<200
14	14:00	13:15	46	193	4.2	<40	<200
Median		13:38	93	235	2.3
IQR 25%		13:00	48	135	1.4
IQR 75%		14:27	167	775	4.1

^aThe interindividual variabilities for the raltegravir concentrations in BP and in CVF and for the ratio of the raltegravir concentration in CVF to that in BP are 127%, 176%, and 159%, respectively. RAL, raltegravir.

^b*, patient with bacterial vaginosis.